SL Science Holding is a Taiwan-based biomedical company developing cell and gene therapies, with a focus on gamma-delta T-cell platforms for solid tumors such as pancreatic and brain cancers. It also works on Armed-T approaches and non-cellular biologics including milk- and plant-derived exosome products, which have contributed commercial revenue in cosmetics and regenerative-care lines. Lead therapeutic programs remain largely preclinical, with the public listing following a SPAC combination.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2023 | 0.9 | — | 0.4 | — |
| 2024 | 3.4 | 282.7% | -1.2 | -398.6% |
| 2025 | 2.2 | -34.7% | -3.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Jade Biosciences, Inc. (JBIO), Prospect Capital Corporation (PSEC), Cryoport, Inc. (CYRX), Bloomin' Brands, Inc. (BLMN), Great Southern Bancorp, Inc. (GSBC), Rigel Pharmaceuticals, Inc. (RIGL)